Latest news with #genomictesting
Yahoo
04-07-2025
- Business
- Yahoo
Thermo Fisher Scientific (NYSE:TMO) Gains FDA Approval for Rapid Cancer Diagnostic Tool
Thermo Fisher Scientific recently achieved a 7% price increase following the FDA approval of its Oncomine™ Dx Express Test. This approval, enabling rapid genomic testing, bolsters the company's position in precision oncology and positively impacts investor sentiment. The FDA's decision in early July underscored Thermo Fisher's commitment to advancing diagnostic solutions, which aligns with industry trends toward expedited drug development. Additionally, its strategic collaborations and new contracts, such as with the U.S. Department of Defense, provide further support to its market performance. Despite a broader market dip earlier this year, Thermo Fisher's recent achievements contributed to its stock recovery. Every company has risks, and we've spotted 1 risk for Thermo Fisher Scientific you should know about. Find companies with promising cash flow potential yet trading below their fair value. The FDA approval of Thermo Fisher's Oncomine™ Dx Express Test may bolster its long-term revenue prospects by enhancing its precision oncology portfolio. This is expected to propel Thermo Fisher's market position within the fast-growing biopharma services sector. The company's revenue and earnings forecasts might see positive adjustments as this product gains market traction, aligning with its focus on innovative diagnostic solutions. The integration of these advancements could support further share price increases toward the consensus price target of US$554.04, representing a potential appreciation from the current share price. Over a five-year period, Thermo Fisher's total shareholder return, including dividends, amounted to 12.13%. This shows moderate growth compared to the challenging conditions experienced by the broader market, particularly over the past year when Thermo Fisher underperformed the US Life Sciences industry, which recorded a 15.6% decline. Analyzing this context, the recent uptick in share price highlights a rebound from earlier market pressures, as investors respond positively to decisive company actions and innovations. Thermo Fisher's recent initiatives and developments aim to counter macroeconomic challenges, although potential risks from tariffs and policy changes remain. Gain insights into Thermo Fisher Scientific's historical outcomes by reviewing our past performance report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:TMO. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
06-06-2025
- Health
- Medscape
ASCO 2025: Key Highlights in Prostate Cancer
Dr Petros Grivas surveys several exciting developments in prostate cancer research, including AI-driven biomarker analysis from the STAMPEDE trial, to identify high-risk patients who may benefit from abiraterone. He also discusses positive results from the AMPLITUDE trial, where adding niraparib to standard therapy improved radiographic progression-free survival, especially in patients with BRCA1 or BRCA2 mutations, reinforcing the need for comprehensive genomic testing. Emerging treatments such as bispecific antibodies and radioligand theranostics, including the impact of lutetium-PSMA and updates from the PSMAddition study, showed promise, though practice-changing data are still forthcoming. He emphasizes the importance of leveraging technology and community collaboration to drive progress and improve outcomes in cancer care.
Sky News
30-05-2025
- Health
- Sky News
New blood test to 'revolutionise' NHS cancer treatment
A new ultra-sensitive blood test which can detect tiny fragments of tumour DNA could be "revolutionary" for NHS patients. Thousands of patients will be offered liquid biopsies, which can help fast-track lung cancer patients to receive targeted treatments. Tissue biopsies are used to confirm a diagnosis of lung cancer and samples can be sent for genomic testing. But liquid biopsies allow for results much faster, and can show patients if they have mutations. Rebeca Proctor, 41, was treated a suspected chest infection last December. After she began coughing up blood, she was diagnosed with stage four cancer - which she called a "punch to the gut". "I was scared - I just thought about my children, and if I would get to see my little girl start nursery, and how I would explain my diagnosis to my children - it was just heartbreaking to think about," the mother of four from Carlisle said. A liquid biopsy showed she had an ALK genetic mutation of her non-small-cell lung cancer. A tissue biopsy took ten days longer to confirm the same result, but in the meantime she could begin a targeted treatment. New medication has "given me my life back", she says. "I'm taking it day-by-day and for now the treatment is doing what it's meant to be doing and shrinking the tumour, and I've got my energy back," she said. "I know I'm not going to be cured but I've come to terms with my diagnosis and the pills are stopping my cancer cells from spreading - we'll keep fighting this and dealing with what's been thrown at us." Breast and lung cancers are two of the most common in England - around 90,000 people are diagnosed with one of them each year. Potential to 'scan' the body in a single blood test NHS England will become the first health service in the world to roll-out a "blood-test first" approach to diagnosing lung cancer, and it follows a successful pilot of the testing last year. Up to 15,000 patients could benefit. The NHS has also said it is expanding testing in advanced breast cancer, with several genetic variations now being screened for. It could save the health service up to £11m per year in lung cancer care. Professor Peter Johnson, NHS national clinical director for cancer, said it would enable patients to receive "more targeted and kinder care", as it would enable some to avoid more intensive treatments - such as chemotherapy - in place of a more targeted approach. "Liquid biopsies are leading us into a new era of personalised cancer care and it's fantastic that we are now able to expand the use of this revolutionary test on the NHS to help tailor treatment for thousands of patients across the country," he said. Liquid biopsies, he added, have the potential to "scan" the body in a single blood test. Professor Dame Sue Hill, Chief Scientific Officer for England, said: "This testing is transforming care and helping clinicians match patients earlier especially when cancer tissue may not be available with potentially life-extending targeted therapies rapidly and with greater precision." The health secretary called it an "incredibly exciting new test" that could save countless lives. "It is just the latest example of this government combining the compassionate care of our National Health Service with the ingenuity of Britain's leading scientific minds to revolutionise cancer care," Wes Streeting said.
Medscape
22-05-2025
- Health
- Medscape
ASCO 2025: Anticipating Key Innovations in Prostate Cancer
Petros Grivas, MD, PhD, expresses great enthusiasm for the 2025 ASCO Annual Meeting, highlighting its wealth of clinical trial data, educational sessions, and real-world insights. He is particularly excited about new findings in prostate cancer, including the AMPLITUDE trial on PARP inhibitors and updates from the IRONMAN registry. He also emphasizes the importance of genomic testing in patient care and looks forward to data on its real-world utilization and potential barriers. Additional highlights include emerging therapeutics like bispecific antibodies and radioligand therapies, including updates on lutetium-PSMA for advanced prostate cancer.
